At #EASCongress2025, Prof. Göran K. Hansson wowed the audience with his talk “How to win a Nobel Prize?”: eas.to/OpenJul25. Drawing on his Nobel Committee experience, he revealed what it really takes: rigorous standards, groundbreaking discoveries, and the long road from research to recognition.
How you can get a grant?
Tips from the best! Judith Sluimer Keith Channon
New #AtheroTalk podcast now available!
Live from #EASCONGRESS2025!!
ENJOY! 👇👇👇👇👇👇👇👇👇👇🤔
open.spotify.com/episode/4ngq...
🎙️New #AtheroTalk Episode – Now Live!
We had the pleasure of speaking with Prof. Noam Zelcer during the #EASCongress2025!
‼️Looking for a PhD? His lab is hiring- deadline soon!!!
🎧Listen now:
Spotify: open.spotify.com/episode/6fdY...
#PhDPosition #SciencePodcast #CardioSky @eassociety.bsky.social
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement .
academic.oup.com/eurheartj/ad...
@eassociety.bsky.social @escardio.bsky.social
#CardioSky #MedSky #EASCongress2025 #EHJ
This week, results from our Phase 3 clinical program were shared in late-breaking sessions at #EASCongress2025 and simultaneously published in two prestigious medical journals. Learn more about the data: ir.newamsterdampharma.com/news-release...
#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social
#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social
@NewAmsPharma announced that once-daily oral obicetrapib significantly lowered LDL-C in patients with ASCVD who do not respond sufficiently to standard therapy in the Phase 3 BROADWAY and TANDEM trials.
🔗 www.hcplive.com/view...
#Cardiology #EASCongress2025
💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇
The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10....
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social
Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014...
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025
While the TANDEM trial has limitations—short follow-up, mainly White participants, and no systematic CV event tracking—if approved, the fixed-dose combo could still offer a valuable new oral option for lowering LDL-C in patients on maximally tolerated LLT #EASCongress2025 @eassociety.bsky.social
Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
@eassociety.bsky.social #EASCongress2025 #lipids #obicetrapib
Our means for lowering LDL cholesterol keeps expanding.
New RCT @nejm.org & @thelancet.bsky.social
1. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
www.nejm.org/doi/full/10....
@eassociety.bsky.social
@newamsterdampharma.bsky.social
#CardioSky #EASCongress2025
Late-breaking data from our Phase 3 BROADWAY clinical trial was presented today at #EASCongress2025 and simultaneously published in the New England Journal of Medicine. Read about the results from our largest Phase 3 study to date: www.nejm.org/doi/full/10....
#EASCongress2025 UPDATE: Data from our Phase 3 TANDEM study was presented in a late-breaking session today. The results were also accepted for simultaneous publication in The Lancet. Explore the latest from this combination study: www.thelancet.com/journals/lan...
In a randomized trial of patients at high cardiovascular risk, the cholesteryl ester transfer protein inhibitor obicetrapib reduced low-density lipoprotein cholesterol levels by 29.9% at 84 days. Full BROADWAY trial results: nej.md/4lKsmMK
@eassociety.bsky.social | #EASCongress2025
Cardiovascular research getting smarter: -omics and generative AI are rewriting the rules! Prof. Manuel Mayr beautifully presents the secrets to unlock cardiovascular disease at #EASCongress2025
Harnessing AI for atherosclerosis phenotyping: a new era in cardiovascular imaging magnificently presented by Prof. Ron Blankstein at #EASCongress2025
Inspiring talk by Sir Rory Collins on UK Biobank: an invaluable resource bringing cardiovascular research to new heights. "Scale, depth, duration...but most importantly, ACCESSIBILITY". #EASCongress2025
Cracking the code to cure cardiovascular disease: Prof. Thomas F. Luscher giving enlightening insights on AI applications for atherosclerosis treatment. #EASCongress2025
What does EAS Young Fellows Programm mean?? It means SCIENCE, PASSION, FRIENDSHIP & a touch of ART — all in one squad! Loving the energy at #EASCongress2025 #EASYoungFellows #MyEAS2025 #AtheroTalk
We are waiting for you at the EAS Stage!!
Social media and the physician: What can we harness?
A powerful reminder of the digital tools at our fingertips to educate, connect, and inspire!
#EAS2025 #EASCongress2025 #EASSoMe
Keeping up with evolving technologies - stem cells, genomics and AI contribution to drug discovery excellently presented by Prof. Joseph Wu at the Hugh Sinclair Lecture today at #EASCongress2025
We’ve just kicked off the E-HEALTH, AI AND BIG DATA workshop at #EAS2025 — where cutting-edge digital health meets clinical impact!
#EASCongress2025 #EASSoMe
